(BSX) Boston Scientific - Overview

Sector: HealthcareIndustry: Medical Devices | Exchange NYSE (USA) | Currency USD | Market Cap: 102.799m | Total Return -37.6% in 12m

Stock Stent, Catheter, Defibrillator, Pacemaker, Endoscope
Total Rating 34
Risk 67
Buy Signal -2.18
Medical Devices -5.4
Health Care Equipment -3.1
Market Cap: 102,799m
Avg Trading Vol: 891M USD
ATR: 2.83%
Peers RS (IBD): 8.8
Risk 5d forecast
Volatility47.5%
Rel. Tail Risk-8.06%
Reward TTM
Sharpe Ratio-1.43
Alpha-47.28
Character TTM
Beta0.645
Beta Downside0.962
Drawdowns 3y
Max DD41.81%
CAGR/Max DD0.20
EPS (Earnings per Share) EPS (Earnings per Share) of BSX over the last years for every Quarter: "2021-03": 0.37, "2021-06": 0.4, "2021-09": 0.41, "2021-12": 0.45, "2022-03": 0.39, "2022-06": 0.44, "2022-09": 0.43, "2022-12": 0.49, "2023-03": 0.47, "2023-06": 0.53, "2023-09": 0.5, "2023-12": 0.55, "2024-03": 0.56, "2024-06": 0.62, "2024-09": 0.63, "2024-12": 0.7, "2025-03": 0.75, "2025-06": 0.75, "2025-09": 0.75, "2025-12": 0.8, "2026-03": 0,
EPS CAGR: -44.22%
EPS Trend: 18.7%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of BSX over the last years for every Quarter: 2021-03: 2752, 2021-06: 3077, 2021-09: 2932, 2021-12: 3127, 2022-03: 3026, 2022-06: 3244, 2022-09: 3170, 2022-12: 3242, 2023-03: 3389, 2023-06: 3599, 2023-09: 3527, 2023-12: 3725, 2024-03: 3856, 2024-06: 4120, 2024-09: 4209, 2024-12: 4561, 2025-03: 4663, 2025-06: 5061, 2025-09: 5065, 2025-12: 5286, 2026-03: null,
Rev. CAGR: 16.04%
Rev. Trend: 98.8%
Last SUE: 0.04
Qual. Beats: 0
Description: BSX Boston Scientific February 27, 2026

Boston Scientific (BSX) designs, manufactures and markets a broad portfolio of medical devices across two primary segments-MedSurg and Cardiovascular-serving specialties such as gastrointestinal, urology, neuromodulation, and cardiac rhythm management. Its product lineup includes endoscopic tools, ureteral stents, spinal cord stimulators, and implantable cardiac devices like the WATCHMAN FLX left-atrial appendage closure system.

In its most recent fiscal year (2023), Boston Scientific reported revenue of $11.5 billion, up roughly 10 % year-over-year, with an operating margin of 24 % and earnings per share of $4.14. The company invested $1.7 billion in R&D, reflecting a continued focus on next-generation minimally invasive technologies, and generated $2.3 billion in operating cash flow, supporting a dividend yield near 0.7 %.

Key sector drivers include an aging U.S. population that is expanding the addressable market for cardiovascular and neuro-interventional devices, accelerating adoption of outpatient and minimally invasive procedures, and favorable reimbursement trends for high-value implantable therapies. These macro-level forces underpin the growth outlook for the broader health-care equipment industry.

For a deeper dive into BSX’s valuation metrics, you might explore ValueRay’s analysis.

Headlines to Watch Out For
  • Cardiovascular device sales drive revenue growth
  • MedSurg segment expands product offerings
  • Regulatory approvals impact new product launches
  • Healthcare spending trends affect device demand
Piotroski VR‑10 (Strict, 0-10) 7.5
Net Income: 2.89b TTM > 0 and > 6% of Revenue
FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.11 > 1.0
NWC/Revenue: 16.71% < 20% (prev 3.11%; Δ 13.60% < -1%)
CFO/TA 0.10 > 3% & CFO 4.53b > Net Income 2.89b
Net Debt (10.37b) to EBITDA (4.91b): 2.11 < 3
Current Ratio: 1.62 > 1.5 & < 3
Outstanding Shares: last quarter (1.50b) vs 12m ago 0.38% < -2%
Gross Margin: 69.01% > 18% (prev 0.61%; Δ 6.84k% > 0.5%)
Asset Turnover: 48.33% > 50% (prev 42.51%; Δ 5.83% > 0%)
Interest Coverage Ratio: 8.33 > 6 (EBITDA TTM 4.91b / Interest Expense TTM 354.0m)
Altman Z'' 1.67
A: 0.08 (Total Current Assets 8.79b - Total Current Liabilities 5.44b) / Total Assets 43.67b
B: 0.13 (Retained Earnings 5.57b / Total Assets 43.67b)
C: 0.07 (EBIT TTM 2.95b / Avg Total Assets 41.53b)
D: 0.26 (Book Value of Equity 4.98b / Total Liabilities 19.20b)
Altman-Z'' Score: 1.67 = BB
Beneish M -3.09
DSRI: 0.95 (Receivables 2.93b/2.56b, Revenue 20.07b/16.75b)
GMI: 0.89 (GM 69.01% / 61.44%)
AQI: 0.95 (AQ_t 0.70 / AQ_t-1 0.73)
SGI: 1.20 (Revenue 20.07b / 16.75b)
TATA: -0.04 (NI 2.89b - CFO 4.53b) / TA 43.67b)
Beneish M-Score: -3.09 (Cap -4..+1) = AA
What is the price of BSX shares? As of March 31, 2026, the stock is trading at USD 62.93 with a total of 43,458,072 shares traded.
Over the past week, the price has changed by -9.51%, over one month by -18.11%, over three months by -34.45% and over the past year by -37.62%.
Is BSX a buy, sell or hold? Boston Scientific has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy BSX.
  • StrongBuy: 23
  • Buy: 8
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BSX price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 101.8 61.8%
Analysts Target Price 101.8 61.8%
BSX Fundamental Data Overview March 31, 2026
P/E Trailing = 35.6546
P/E Forward = 20.1207
P/S = 5.121
P/B = 4.2547
P/EG = 0.7501
Revenue TTM = 20.07b USD
EBIT TTM = 2.95b USD
EBITDA TTM = 4.91b USD
Long Term Debt = 11.14b USD (from longTermDebt, last quarter)
Short Term Debt = 389.0m USD (from shortTermDebt, last quarter)
Debt = 12.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.37b USD (from netDebt column, last quarter)
Enterprise Value = 113.25b USD (102.80b + Debt 12.42b - CCE 1.97b)
Interest Coverage Ratio = 8.33 (Ebit TTM 2.95b / Interest Expense TTM 354.0m)
EV/FCF = 31.24x (Enterprise Value 113.25b / FCF TTM 3.62b)
FCF Yield = 3.20% (FCF TTM 3.62b / Enterprise Value 113.25b)
FCF Margin = 18.06% (FCF TTM 3.62b / Revenue TTM 20.07b)
Net Margin = 14.40% (Net Income TTM 2.89b / Revenue TTM 20.07b)
Gross Margin = 69.01% ((Revenue TTM 20.07b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 74.50% (prev 69.93%)
Tobins Q-Ratio = 2.59 (Enterprise Value 113.25b / Total Assets 43.67b)
Interest Expense / Debt = 0.72% (Interest Expense 90.0m / Debt 12.42b)
Taxrate = 4.43% (31.0m / 700.0m)
NOPAT = 2.82b (EBIT 2.95b * (1 - 4.43%))
Current Ratio = 1.62 (Total Current Assets 8.79b / Total Current Liabilities 5.44b)
Debt / Equity = 0.51 (Debt 12.42b / totalStockholderEquity, last quarter 24.23b)
Debt / EBITDA = 2.11 (Net Debt 10.37b / EBITDA 4.91b)
Debt / FCF = 2.86 (Net Debt 10.37b / FCF TTM 3.62b)
Total Stockholder Equity = 23.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.96% (Net Income 2.89b / Total Assets 43.67b)
RoE = 12.53% (Net Income TTM 2.89b / Total Stockholder Equity 23.06b)
RoCE = 8.62% (EBIT 2.95b / Capital Employed (Equity 23.06b + L.T.Debt 11.14b))
RoIC = 8.19% (NOPAT 2.82b / Invested Capital 34.42b)
WACC = 7.44% (E(102.80b)/V(115.22b) * Re(8.25%) + D(12.42b)/V(115.22b) * Rd(0.72%) * (1-Tc(0.04)))
Discount Rate = 8.25% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.64%
[DCF] Terminal Value 83.46% ; FCFF base≈3.15b ; Y1≈3.89b ; Y5≈6.63b
[DCF] Fair Price = 79.75 (EV 128.90b - Net Debt 10.37b = Equity 118.52b / Shares 1.49b; r=7.44% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 18.74 | EPS CAGR: -44.22% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.82 | Revenue CAGR: 16.04% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.86 | Chg7d=-0.001 | Chg30d=-0.003 | Revisions Net=-4 | Analysts=24
EPS current Year (2026-12-31): EPS=3.47 | Chg7d=-0.002 | Chg30d=+0.002 | Revisions Net=-9 | Growth EPS=+13.3% | Growth Revenue=+10.9%
EPS next Year (2027-12-31): EPS=3.91 | Chg7d=-0.004 | Chg30d=-0.007 | Revisions Net=-7 | Growth EPS=+12.8% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: -0.67 (1 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.4% (Discount Rate 8.2% - Earnings Yield 2.8%)
[Growth] Growth Spread = +4.4% (Analyst 9.8% - Implied 5.4%)
Additional Sources for BSX Stock Fund Manager Positions: Dataroma · Stockcircle